BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 21900880)

  • 1. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
    Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.
    Bendel-Stenzel MR; Steinke J; Dohil R; Kim Y
    Pediatr Nephrol; 2008 Feb; 23(2):311-5. PubMed ID: 17668247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of nephropathic cystinosis: a 20-year single-center experience.
    Greco M; Brugnara M; Zaffanello M; Taranta A; Pastore A; Emma F
    Pediatr Nephrol; 2010 Dec; 25(12):2459-67. PubMed ID: 20803298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
    Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
    J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cystinosis in adults: A systemic disease].
    Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
    Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up and treatment of renal transplantation with nephropathic cystinosis in central Taiwan.
    Chuang YW; Wen MC; Wu MJ; Shu KH; Cheng CH; Yu TM; Huang ST; Chen CH
    Transplant Proc; 2012 Jan; 44(1):80-2. PubMed ID: 22310585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis.
    Kimonis VE; Troendle J; Rose SR; Yang ML; Markello TC; Gahl WA
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3257-61. PubMed ID: 7593434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
    da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
    N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
    Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
    BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early oral cysteamine therapy for nephropathic cystinosis.
    Gahl WA
    Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephropathic cystinosis: late complications of a multisystemic disease.
    Nesterova G; Gahl W
    Pediatr Nephrol; 2008 Jun; 23(6):863-78. PubMed ID: 18008091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.